Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.24 USD | -0.72% | -6.34% | -19.63% |
23/05 | Bristol-Myers Squibb Unveils Positive Data for KarXT in Schizophrenia Treatment | MT |
22/05 | Bristol Myers, Sanofi liability in Hawaii Plavix case grows to $916 million | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.63% | 8.36TCr | |
+38.51% | 73TCr | |
+33.05% | 60TCr | |
-6.23% | 35TCr | |
+18.78% | 33TCr | |
+1.35% | 28TCr | |
+16.00% | 24TCr | |
+8.09% | 20TCr | |
-5.77% | 20TCr | |
+6.19% | 16TCr |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- Bristol Myers Squibb : BofA Notes Bristol-Myers Squibb's $20 Billion Product Cycle Revenue Potential; Reiterates Buy Rating With $80 Price Objective